HIGHLIGHTS
- who: Steven C. Cramer et al. from the University of have published the research: Human Choriogonadotropin and Epoetin Alfa in Acute Ischemic Stroke Patients (REGENESIS-LED Trial), in the Journal: (JOURNAL)
- how: Prior to study initiation an Investigators' Meeting was conducted to provide information and training to all site and sponsor staff including training in the performance of each outcome measure.
SUMMARY
Preclinical studies suggest that growth factors in the early days after stroke improve final outcome. A prior study found three doses of human choriogonadotropin alfa followed by three doses . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.